anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Compare the clinical severity of second preeclampsia with the first preeclampsia.
METHODS: This retrospective longitudinal cohort study was conducted in three teaching hospitals in Guangzhou, where there were a total of 296 405 deliveries between 2010 and 2021. Two consecutive singleton deliveries complicated with preeclampsia were included. Clinical features, laboratory results within 1 week before delivery, and maternal and neonatal outcomes of both deliveries were collected. Univariate analyses were made using paired Wilcoxon tests and McNemar tests. Multivariable logistic regression and generalized linear models were performed to assess the association of adverse maternal and neonatal outcomes with second preeclampsia.
RESULTS: A total of 151 women were included in the study. The mean maternal age was 28 and 33 years for the first and second deliveries, respectively. The proportion of preventive acetylsalicylic acid use was 4.6% for the first delivery and 15.2% for the second delivery. No significant differences were observed in terms of blood pressure on admission, gestational weeks of admission and delivery, application of perinatal antihypertensive agents, rates of preterm delivery, and severe features between the two occurrences. However, the rates of heart disease, edema, and admission to the ICU were lower, and hospital stays were shorter in the second preeclampsia compared with the first preeclampsia. Sensitivity analysis conducted among women who did not use preventive acetylsalicylic acid yielded similar results. After adjusting for potential confounding variables, the occurrence of second preeclampsia was associated with significantly decreased risks of heart disease, edema, complications, and admission to the NICU, with odds ratios ranging between 0.157 and 0.336.
CONCLUSION: Contrary to expectations, the second preeclampsia did not exhibit worse manifestations or outcomes to the first occurrence. In fact, some clinical features and outcomes appeared to be better in the second preeclampsia.
PROBLEM TO BE SOLVED: To obtain a percutaneous absorption-stimulating preparation for external use for skin, excellent in a roughened skin-improving effect by compounding a carboxylic acid derivative, water and one of polysaccharides. SOLUTION: This percutaneous absorption-stimulating preparation for external use for skin contains a carboxylic acid derivative as a water-soluble physiologically active ingredient, water and one or more kinds of polysaccharides. The carboxylic acid derivative and the polysaccharide are compounded in amounts of 0.01-5wt.% and 0.01-2wt.%, respectively. The carboxylic acid derivative is e.g. γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, and the polysaccharide is e.g. xanthane gum, carrageenan. The preparation can be applied to cosmetics and medicines. The ingredients in the percutaneous absorption- stimulating preparation for external use for skin act on the skin to stimulate the percutaneous absorption of the carboxylic acid derivative and accelerate the functions of the skin.  Therefore, the preparation can allow to express an excellent roughened skin-improving effect in a short time and sustain the effect.
Despite mounting evidence linking Acute Myocardial Infarction (AMI) to Alzheimer's disease (AD), the shared mechanism of these two conditions' occurrence remains unclear. This research aims to delve deeper into the molecular process of the occurrence of the two diseases. We retrieved the gene expression profiles of AD (GSE5281) and AMI (GSE66360) from the Gene Expression Omnibus database. Then, a total of 22 common differentially expressed genes (DEGs) including one downregulated gene and 21 upregulated genes were chosen for further analysis. Following the discovery of the common DEGs between AMI and AD, we performed protein-protein interaction analysis and hub gene identification analysis. Next, ten important hub genes were identified. Additionally, the key genes were identified by the least absolute shrinkage and selection operator and support vector machine-recursive feature elimination and multivariable logistic regression analysis. The BCL6 was identified to be the most connected with AMI and AD. Finally, the BCL6 gene was validated in the GSE40680 (AMI) and GSE122063 (AD) datasets. Our research indicates that AMI and AD share a comparable pathophysiology. The Hub genes, especially BCL6, were essential in developing AMI and AD. In addition, these hub genes and shared pathways can offer fresh perspectives for additional mechanism investigation.
The present invention discloses a cold evil-expelling Shengqisixiang bolus, which relates to a Chinese herbal medicine for curing enteritis, intestinal chilliness and other diseases. The cold evil-expelling Shengqisixiang bolus is developed for mainly solving the problem that the existing medicament for curing enteritis, intestinal chilliness and other diseases has the disadvantages of long course of treatment, slow effect, etc. The cold evil-expelling Shengqisixiang bolus is mainly prepared from 24 kinds of Chinese herbal medicines comprising astragalus root, Atractylodis Macrocephalae, cassia, fennel, clove, aucklandia root, Chiese eaglewood wood, white peony root, Diyutan, prepared rhizome of rehmannia, scutellaria root, dried tangerine peel, etc. as raw materials which are made into a bolus through processing. The cold evil-expelling Shengqisixiang bolus is used for curing enteritis and intestinal chilliness, regulating vital energy quickly, alleviating pain and reducing acid, discharging cold stasis as soon as possible and repairing goldbeater's skin. The cold evil-expelling Shengqisixiang bolus can take effect in one month.
An apparatus for magnetic cell separation using paramagnetic microbeads includes a base upon which is movably carried a rocker member. The rocker member carries both a primary processing container in which a mixture of liquid with cells and paramagnetic microbeads is received; and a primary magnet movable from a first position adjacent to the primary container to magnetically capture the microbeads, and a second position spaced from the primary container to magnetically release the microbeads. The mixture of liquid with cells and microbeads is agitated by tilting motions of the rocker assembly, thereby achieving the binding of target cells to microbeads. The paramagnetic microbeads, with bound target cells, are captured and released by movements of the primary magnet between its first and second positions. A secondary magnet is placed downstream from the primary magnet to capture any paramagnetic microbeads which might escape from the primary magnet. Also provided is an interconnected container apparatus for use to contain and appropriately conduct the liquid, cells, and microbeads.
BACKGROUND: The identification of associated overweight risk factors is crucial to future health risk predictions and behavioral interventions. Several consensus problems remain in machine learning, such as cross-validation, and the resulting model may suffer from overfitting or poor interpretability.
METHODS: This study employed nine commonly used machine learning methods to construct overweight risk models. The general community are the target of this study, and a total of 10,905 Chinese subjects from Ningde City in Fujian province, southeast China, participated. The best model was selected through appropriate verification and validation and was suitably explained.
RESULTS: The overweight risk models employing machine learning exhibited good performance. It was concluded that CatBoost, which is used in the construction of clinical risk models, may surpass previous machine learning methods. The visual display of the Shapley additive explanation value for the machine model variables accurately represented the influence of each variable in the model.
CONCLUSIONS: The construction of an overweight risk model using machine learning may currently be the best approach. Moreover, CatBoost may be the best machine learning method. Furthermore, combining Shapley's additive explanation and machine learning methods can be effective in identifying disease risk factors for prevention and control.
FIELD: chemistry. ^ SUBSTANCE: invention refers to the group including hydronopol-substituted benzimidazolone- and quinazolinone-derivatives as agonists of human ORL1 receptors (nociceptors). In addition, the invention refers to making specified compounds, to pharmaceutical compositions containing pharmacologically active amount of at least one specified new benzimidazolone- and quinazolinone-derivatives as an active component, and to application of said pharmaceutical compositions in treatment of disorders involving ORL1 receptors. The invention concerns compounds of general formula where symbols take on values specified in the description. ^ EFFECT: higher effectiveness of the composition and therapy. ^ 7 cl, 17 ex, tbl
Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
The invention relates to the utilization of xanthines, optionally incorporated in liposomes in order to favour the pigmentation of skin or hair. The xanthine has formula (I), or a salt thereof, or a vegetal extract containing it, wherein: particularly R1? and R4? represent each a hydrogen atom and R1? and R2?, similar or different, represent each a hydrogen atom or an alkyl radical having preferably from 1 to 4 carbon atoms. This xanthine, optionally incorporated in liposomes, is used for the preparation of a cosmetic or pharmaceutical, particularly dermatological composition for the pigmentation of hair or skin or to reinforce the natural defences of skin against solar radiation.
In this study, we aimed to explore the clinical significance of serum CK18-M65 and CK18-M30 levels in patients with chronic hepatitis B (CHB) complicated by nonalcoholic steatohepatitis (NASH) and liver fibrosis. The observation and control groups comprised 133 patients with CHB complicated by NASH and 50 healthy patients from our hospital, respectively. Liver function indices, including alanine aminotransferase, glutamic aminotransferase, γ-glutamyltransferase, total bilirubin, total protein, and total cholesterol, were determined using an automatic biochemical analyzer. Hyaluronic acid, type III procollagen, type IV collagen, laminin, and CK18-M65 and M30 levels were detected using ELISA. Serum CK18-M65 and M30 levels in patients with CHB complicated by NASH were positively correlated with the liver fibrosis stage (P < .05). While serum CK18-M65 demonstrated a low diagnostic value for liver fibrosis in the S0-1 stage, it exhibited good diagnostic value for S2-3 stage liver fibrosis. Serum CK18-M30 displayed good diagnostic value for S0-1 and S2-3 hepatic fibrosis, particularly for S2-3 hepatic fibrosis. Elevated serum CK18-M65 and CK18-M30 levels in patients with CHB complicated with NASH suggest their potential utility in evaluating the progression of liver fibrosis in this population. In particular, CK18-M30 exhibits superior diagnostic efficiency.
The embodiment of the invention provides a method, a device, equipment and a storage medium for predicting drug interaction, and relates to the technical field of medicines. The prediction method comprises steps S1 to S9. S1 obtains characteristics of the plurality of drugs and types of reactions between the drugs. S2 constructing a drug feature matrix according to the features of the plurality of drugs. S3 constructing a drug adjacency graph according to the reaction type among a plurality of drugs. S4 extracting the medicine characteristic information of different levels from the medicine characteristic matrix through the deep neural network. S5 extracting neighbor topological structure information of different levels from the medicine adjacency graph through a convolutional neural network. S6 fuses the feature vectors and the structure vectors to obtain the final embedded representation of each drug. S7 combines the final embedded representations of the individual drugs to obtain a plurality of drug pair vectors. S8, the response type of the drug pair is used as a label, the drug pair quantity is used as a training data set, and a classification model is obtained through training. S9 predicts the interaction type of the unknown drug pair through a classification model.
The present disclosure is related to a mixture of the leaf and pit or seed of dehydrated avocados packed in bulk, in a 200 grams presentation, or in tea bags with 2 grams of mixture; and once infused, the user can obtain a drink that brings significant health benefits. The elaboration of nutraceutical avocado tea, like any other tea, includes the following stages: a) Reception of the raw material, ensuring that the leaf is originated in orchards with organic certification, free of chemical pesticides and toxic substances, with the corresponding certificates from the home orchard, and in turn, the laboratory results validating the acceptance of the raw material. The pit must be presented in a polyethylene package, which in turn is packed in plastic boxes. b) Selection of raw material: the leaves and pits that have the best appearance and quality characteristics are selected, taking into account sensory parameters, such as smell, color and texture, which should be characteristic of the raw materials. Discarding any contaminant outside its own nature. c) Washing and disinfecting: Raw materials are washed with drinking water and neutral food grade detergent to remove foreign matter, disinfected in a chlorine solution at a concentration of 50 ppm for periods of 5 minutes and rinsed with drinking water. d) First grinding: the pit and leaves are resized separately in an industrial blender for 1 minute, achieving a particle size of no more than 5 millimeters. e) Dehydration: The raw materials are subjected to a dehydration process in a forced draft oven, at a temperature of 60°C, for 6 hours, until a 10% of humidity is obtained. f) Second grinding: the particle size of the raw materials in a ball mill is reduced at 60 rpm, for a time of one minute. g) Mixing: The mixing of the raw materials is carried out, combining 40% of pit with 60% of leaf. h) Packaging and labeling: the seed and leaf mixture is placed in the pre-calibrated packing machine, placing two grams of mixture in each bag of filter paper. Once the bags are formed, 25 bags are packed in preformed cardboard boxes that are labeled and sealed.
Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle.
Art therapy is a type of psychotherapy that uses making art and creative processes to allow patients to express feelings that may be difficult to put into words. It has been available at The Royal Marsden NHS Foundation Trust since 1988. Patients are referred for a range of issues that include isolation, anxiety, depression, identity or end of life issues. Research has shown art therapy to offer significant improvements in these areas. There is much anecdotal evidence within art therapy of it's effectiveness for physical pain, but little research in this area. Pain itself is acknowledged as a complex phenomena that demands a multifocused approach to treatment. The British Pain Society's guidelines recommend a combined approach to treatment that includes psychological and complementary therapies, but although music therapy is cited, art therapy is not. This study proposes to broaden the research base into art therapy's effectiveness as an additional intervention to support patients managing physical pain, and thus be able to be offered as additional support to the interventions currently on offer.

Art therapy would, in practice be able to be offered concurrently to all other treatments for pain, and at at any point in the treatment journey. However for the purpose of this study, in order to understand art therapy's potential effectiveness, it is useful to narrow the focus of the research. It is reported that up to 50% of breast cancer patients suffer from chronic post treatment pain, that is, for an extended period of time after all treatment for cancer and despite being optimally treated already for their pain. In consultation with the Pain Team at the RM it was decided that breast cancer patients were a suitable cohort for this study.

As this is the first study at the RM looking into art therapy and physical pain, it was decided that a mixed method study would produce the most valuable data. Narrative data from interviews will allow a greater understanding of participants experience of art therapy, and how it might be effective for pain. Numerical data will give information on the extent of how effective for pain art therapy might be. The sample size is small (20 participants) in order to allow for in depth analysis of the narrative data. Previous research studies looking at art therapy in oncology have offered between a single, to eight, one hour individual art therapy sessions. Art therapy research in oncology that included pain as a criteria for study, has offered a single, hour long session and examined data on its impact on pain collected immediately after the art therapy session. As this study proposes to explore art therapy as an intervention that may offer benefits for pain that develop over time, four, hour long individual art therapy sessions have been decided on. This allows for an understanding of whether art therapy may have any effect on pain beyond an immediate lessening during an art therapy session.
The general objective of this study is to determine the safety and efficacy of GRFA in patients with failed TKA. The central hypothesis is that GRFA is safe and more efficacious in improving pain and function than sham GRFA. A triple blinded randomized sham-controlled trial design will be used. Patients with failed TKA will be recruited and randomized into either a thermal or sham GRFA group. Patient selection criteria and GRFA procedural technique will incorporate refinements based on expanded understanding from recent research. Outcomes will be assessed prior to and at 3, 6 and 12 months post-GRFA. The primary outcome measures will be change in pain (NRS). Secondary outcomes will include safety and changes in function (WOMAC; sit-stand test; strength; range of motion \& balance), participants' impression of change, perceived need for revision arthroplasty, analgesic use, and quality-of-life. Crossover will be offered to participants in the sham group at 6 months post-treatment. Data will be analyzed using descriptive, linear mixed-effects model and Kaplan-Meier Survival Curve statistics. The proposed research is innovative and important as it uses a robust study design to evaluate the safety and efficacy of an emerging RFA intervention in a prevalent suffering patient population.
Several institutions and groups have contributed important insight into the understanding of vascular injury management. However, many of the studies have been single-institution, poorly powered and retrospective. The lack of evidence-based practice is even more concerning given the devastating consequences associated with mismanaged vascular trauma. In light of the stated challenges associated with single-institution study of this injury pattern, the logical method with which to proceed is a prospective, multicenter, observational trail. To date no such registries exists which would allow the prospective aggregation of larger amounts of data pertaining to all phases of vascular trauma management.

Contemporary experience confirms that the management of vascular injury is more complicated than in the past. A multitude of new or updated diagnostic technologies including computed tomography angiography (CTA), magnetic resonance angiography (MRA), duplex and arteriography now exist and are in various degrees of vogue. A damage control approach to vascular trauma is widely championed and includes options for the use of tourniquets, temporary vascular shunts and fasciotomies. Controversies regarding the definitive management of vascular trauma abound and include the advisability of open versus endovascular treatment, decisions about the type of vascular conduit and the utility of venous injury repair lo list a few. Recommendations for surveillance after vascular trauma may include the use of duplex ultrasound or CTA to confirm long-term patency as well as choices related to the use of long-term anti-thrombotic therapy. Finally, it is not uncommon for an institution to find itself facing many of these decision points in the most challenging of all scenarios, the extremes of age including pediatric vascular injury.
Modulation or stimulation of the nerves supplying the lower urinary tract is a possible treatment option for dysfunction of the lower urinary tract, pelvic floor and rectum if conservative or minimally invasive treatment approaches fail. This overview shows the possibilities and limitations of sacral neuromodulation, sacral deafferentation with sacral anterior root stimulation and conus deafferentation.Sacral neuromodulation (SNM) is a procedure for the treatment of refractory pelvic floor dysfunction of various origins (idiopathic, neurogenic or post-operative), such as overactive bladder, non-obstructive retention and faecal incontinence. A particular advantage of SNM is the possibility of prior test stimulation with a high prognostic value. The procedure is minimally invasive, reversible and associated with relatively low morbidity rates.Following the introduction of MRI-compatible SNM systems, there has been renewed interest in the treatment of neurogenic bladder dysfunction. A recent meta-analysis reports similar success rates as in the idiopathic patient population.Sacral deafferentation with implantation of a sacral anterior root stimulator (SARS/SDAF) is an excellent therapeutic option for patients with spinal cord injury, which can significantly improve the quality of life of those affected and, in addition to treating neurogenic lower urinary tract dysfunction, can also have a positive effect on neurogenic bowel dysfunction, neurogenic sexual dysfunction or autonomic dysreflexia. If conservative or minimally invasive treatment fails, it is crucial for the success of this procedure to consider SDAF/SARS at an early stage in order to avoid irreversible organic damage.Conus deafferentation (KDAF) is a less invasive surgical treatment option for patients with spinal cord injury for whom sacral deafferentation would be indicated but who would not benefit from the simultaneous implantation of a sacral anterior root stimulator. In principle, these patients also have the option of being subsequently treated with an extradural implant and thus utilising the advantages of anterior root stimulation. Indications for KDAF are autonomic dysreflexia, therapy-refractory detrusor overactivity, recurrent urinary tract infections, urinary incontinence and spasticity triggered by detrusor overactivity. With KDAF, we have a safe and efficient procedure with great potential for improving the spectrum of paraplegiological and neuro-urological treatment.